Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press33510.36691/RJA335ArticlesСтатьиResearch ArticleFixed drug eruption in the practice of the allergist-immunologistЛекарственная фиксированная эритема в практике врача аллерголога-иммунологаRomanovaT SРомановаТ Сtsromanova@mail.ruMyasnikovaT NМясниковаТ НKhludovaL GХлудоваЛ ГLatyshevaT VЛатышеваТ ВInstitute of ImmunologyФГБУ «ГНЦ Институт иммунологии» ФМБА15022017141NO1 (2017)№1 (2017)364010032020Copyright ©; 2017, Pharmarus Print MediaCopyright ©; 2017, Фармарус Принт Медиа2017Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/335

Fixed drug eruption is a type of allergic reaction to a medicine. The mechanism of this disease is delayed type of hypersensitivity. The spectrum of causative medicines can be variable. A careful history and drug provocation tests in vivo in most cases allow to make a diagnosis accurately and identify the offending drug allergen.

Фиксированная эритема относится к достаточно распространенным поражениям кожи при лекарственной аллергии. Механизмом развития данного заболевания является гиперчувствительность замедленного типа. Спектр причинно-значимых препаратов может быть различным. Тщательно собранный фармакологический анамнез и провокационные тесты in vivo в большинстве случаев позволяют точно установить диагноз и выявить антиген - лекарственное средство.

drug allergyfixed drug eruptionapplication testdrug provocative testлекарственная аллергияфиксированная эритемааппликационный тестпровокационный дозируемый тестHunziker T., Kunzi U.P., Braunschweig S. et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997, v. 52, p. 388-393Turk B.G., Gunaydin A., Ertam I., Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan. Ocul. Toxicol. 2013, v. 32 (1), p. 41-45.Ozkaya-Bayazit E., Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J. Am. Acad. Dermatol. 2001, v. 45, p. 712-717.Brahimi N., Routier E., Raison-Peyron N. et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur. J. Dermatol. 2010, v. 20, p. 461-464.Andrade P., Brinca A., Gonçalo M. Patch testing in fixed drug eruptions - a 20-year review. Contact Dermatitis. 2011, v. 65, p. 195-201.Ring J., Blaser K., Capron M. et al. Adverse cutaneous drug eruption. Chem. Immunol. Allergy. 2012, v. 97, p. 240.Korkij W., Soltani K. Fixed drug eruption. Arch. Dermatol. 1984, v. 120, p. 520-524.Mizukawa Y., Shiohara T. Trauma-localized fixed drug eruption: involvement of burn scars, insect bites and venipuncture sites. Dermatology. 2002, v. 205, p. 159-161.Sigal-Nahum M., Konqui A., Gaulier A. et al. Linear fixed drug eruption. Br. J. Dermatol. 1988, v. 118, p. 849-851.Senturk N., Yanik F., Yildiz L. et al. Topotecan - induced cellulitis like fixed drug eruption. J. Eur. Acad. Dermatol. Venereol. 2002, v. 16, p. 414-416.Guin J.D., Baker G.F. Chronic fixed drug eruption caused by acetaminophen. Cutis. 1988, v. 4, p. 106-108.Rijlaarsdam U., Scheffer E., Meijer C.J. et al. Mycosis fungoi-des - like lesions associated with phenytoin and carbamazepine therapy. J. Am. Acad. Dermatol. 1991, v. 24, p. 216-220.Shiohara T., Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmune Rev. 2005, v. 4, p. 236-241.Shelley W.B., Shelley E.D. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J. Am. Acad. Dermatol. 1987, v. 17, p. 403-407.Desmeules H. Nonpigmenting fixed drug eruption after anesthesia. Anesth. Analg. 1990, v. 70, p. 216-217.Barbaud A., Goncalo M., Bruynzeel D. et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001, v. 45, p. 321-328.